Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Feb 23 04:00PM ET
Dollar change
Percentage change
Index- P/E- EPS (ttm)-2.01 Insider Own30.03% Shs Outstand8.14M Perf Week-6.49%
Market Cap14.64M Forward P/E- EPS next Y-2.54 Insider Trans0.00% Shs Float7.12M Perf Month-8.86%
Income-18.02M PEG- EPS next Q-0.60 Inst Own6.71% Short Float0.04% Perf Quarter-11.66%
Sales0.00M P/S- EPS this Y56.11% Inst Trans-2.48% Short Ratio0.16 Perf Half Y-50.34%
Book/sh3.02 P/B0.48 EPS next Y-21.50% ROA-46.05% Short Interest0.00M Perf Year-28.00%
Cash/sh2.93 P/C0.49 EPS next 5Y- ROE-48.31% 52W Range1.33 - 3.29 Perf YTD-16.39%
Dividend Est.- P/FCF- EPS past 5Y-175.59% ROI-58.72% 52W High-56.16% Beta1.34
Dividend TTM- Quick Ratio16.74 Sales past 5Y-42.33% Gross Margin- 52W Low8.68% ATR (14)0.11
Dividend Ex-Date- Current Ratio16.74 EPS Y/Y TTM83.73% Oper. Margin0.00% RSI (14)38.32 Volatility8.75% 6.85%
Employees12 Debt/Eq0.00 Sales Y/Y TTM- Profit Margin- Recom1.00 Target Price8.33
Option/ShortNo / Yes LT Debt/Eq0.00 EPS Q/Q41.40% Payout- Rel Volume0.52 Prev Close1.45
Sales Surprise- EPS Surprise22.64% Sales Q/Q- EarningsNov 13 BMO Avg Volume15.84K Price1.44
SMA20-7.20% SMA50-13.58% SMA200-31.67% Trades Volume8,226 Change-0.69%
Date Action Analyst Rating Change Price Target Change
Jul-08-20Initiated H.C. Wainwright Buy $5
Jan-04-24 08:00AM
Dec-06-23 08:00AM
Nov-29-23 08:00AM
Nov-27-23 08:00AM
Nov-13-23 08:00AM
08:00AM Loading…
Nov-09-23 08:00AM
Oct-31-23 08:00AM
Oct-02-23 12:14PM
Sep-28-23 08:00AM
Sep-05-23 08:00AM
Aug-16-23 09:11AM
Aug-14-23 08:00AM
Aug-08-23 08:00AM
May-31-23 08:00AM
May-17-23 09:26AM
08:00AM Loading…
May-15-23 08:00AM
May-04-23 04:05PM
Apr-24-23 08:00AM
Apr-18-23 08:00AM
Apr-10-23 08:30AM
Mar-31-23 10:05AM
Mar-29-23 08:00AM
Mar-22-23 01:03PM
Jan-26-23 08:00AM
Jan-23-23 09:00AM
Dec-19-22 08:00AM
Dec-01-22 04:05PM
Nov-17-22 01:38PM
11:19AM Loading…
Nov-15-22 11:19AM
Nov-14-22 08:00AM
Nov-02-22 08:00AM
Nov-01-22 04:05PM
Oct-26-22 08:00AM
Oct-19-22 08:00AM
Oct-13-22 08:00AM
Oct-11-22 11:51AM
Oct-05-22 08:00AM
Oct-03-22 04:05PM
Sep-06-22 10:05AM
Aug-19-22 08:10AM
Aug-15-22 08:00AM
Aug-08-22 08:00AM
Aug-03-22 09:00AM
Jul-14-22 08:00AM
Jun-01-22 08:00AM
May-18-22 08:00AM
May-12-22 08:12AM
May-11-22 08:00AM
Apr-21-22 08:00AM
Apr-19-22 08:00AM
Apr-14-22 08:00AM
Apr-12-22 11:01AM
Apr-06-22 10:15AM
Mar-30-22 02:57PM
Mar-25-22 07:30AM
Mar-23-22 04:05PM
Mar-22-22 08:00AM
Mar-10-22 08:00AM
Mar-03-22 08:00AM
Feb-24-22 08:10AM
Jan-27-22 12:22PM
Jan-11-22 07:00AM
Jan-10-22 04:10PM
Jan-06-22 08:00AM
Jan-04-22 08:00AM
Dec-22-21 08:00AM
Dec-02-21 08:00AM
Dec-01-21 04:05PM
Nov-15-21 12:25PM
Nov-08-21 03:00PM
Nov-01-21 08:00AM
Oct-21-21 08:00AM
Oct-14-21 08:00AM
Oct-06-21 08:49AM
Oct-01-21 07:04AM
Sep-07-21 08:00AM
Aug-16-21 09:25AM
Jul-29-21 03:04PM
Jun-28-21 08:00AM
Jun-23-21 08:00AM
Jun-15-21 12:03PM
Jun-14-21 09:48AM
Jun-09-21 02:30PM
May-28-21 08:00AM
May-17-21 08:00AM
May-07-21 04:05PM
May-05-21 09:25AM
May-04-21 06:41PM
Cocrystal Pharma, Inc. is a biotechnology company, which engages in the discovery and development of novel antiviral therapeutics. It focuses on the preclinical and early clinical stage antiviral compounds for unmet medical needs including influenza, Hepatitis C virus, and norovirus infections. The company was founded in 2008 and is headquartered in Bothell, WA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
FROST PHILLIP MD ET ALDirectorApr 04Buy1.971,015,2292,000,0011,319,838Apr 06 04:01 PM